

**Express Mail Label No.: EV 317 172 277 US**  
**Date: February 13, 2004**

**Docket No.: VPI/99-109 DIV US**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Jeremy Green, et al.  
DIVISIONAL OF: 10/074,177 EXAMINER: Deepak R. Rao  
FILING DATE: February 13, 2004 ART UNIT: 1624  
FOR: INHIBITORS OF c-JUN N TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES

February 13, 2004  
Cambridge, Massachusetts

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. (37 C.F.R. §1.97).

A copy of the references are enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the


APPLICANTS: Green, et al.  
U.S.S.N.: Not Yet Assigned

cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0725, Reference No. VPI/99-109 DIV US.

Respectfully submitted,



Karoline K. M. Shair, Reg. No. 44,332  
Attorney for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6536  
Fax: (617) 444-6483

Modified Form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	Not Yet Assigned
	<b>Filing Date</b>	February 13, 2004
	<b>First Named Inventor</b>	Jeremy Green
	<b>Group Art Unit</b>	1624
	<b>Examiner Name</b>	Deepak R. Rao
	<b>Attorney Docket Number</b>	VPI/99-109 DIV US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	4,876,252	10/24/89	Torley, et al.			
	A2	5,356,897	10/18/94	Oku, et al.			

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	B1	Hassan, et al., "Synthesis and Reactions of 5-(D-arabino-tetrahydroxybutyl)-3-(2,3-dihydro-1,3,4-oxadiazole-2-thion-5-yl)-2-methylfuran and 5-(D-arabino-tetrahydroxybutyl)-3-(2-substitued amino-1,3,4-oxadiazol-5-yl)-2-methylfuran", <i>Carboh. Res.</i> , 298:123-126 (1997).
	B2	Paul, et al., "Preparation of Substituted N-Phenyl-4-aryl-2-pyrimidinamines as Mediator Release Inhibitors", <i>J. Med. Chem.</i> , 36:2716-2725 (1993).
	B3	Khisamutdinov, et al., "Some Reactions of 3-phenyl-5-methyl-4-isoxazole-carboxylic acid Hydrazide", <i>Khim. Farm. Zh.</i> , 2(8):35-37 (1968).
	B4	Sokolov, et al., "Isoxazole Compounds - (III) Synthesis of Some Isoxazolylazoles", <i>Zhor. Obshchei Khim.</i> , 30:1781-1787 (1960).
	B5	Ihle, N., et al., "Preparation of 4-Alkyl-2-[N-(tert-butoxycarbonyl)amino]-pyridines by Alkylation, Nucleophilic Addition, and Acylation of 2[N-(tert-butoxycarbonyl)amino]-4-picoline", <i>J. Org. Chem.</i> , 61:4810-4811 (1996).

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.